ASCO 2024 | Key unmet needs in the treatment of neurofibromatosis-associated PN

Christopher Moertel • 31 May 2024

ASCO 2024

General

Christopher L. Moertel, MD, University of Minnesota, Minneapolis, MN, discusses neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) and the unmet medical need for effective treatments. Dr Moertel highlights the potential of mirdametinib, an investigational MEK inhibitors, to address the disfigurement, pain, and impaired quality of life associated with NF1-PN in adults, who currently have no approved therapies.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Employment – OX2 Therapeutics
Leadership – OX2 Therapeutics
Stock and Other Ownership Interests – OX2 Therapeutics
Consulting or Advisory Role – Alexion Pharmaceuticals
Patents, Royalties, Other Intellectual Property – OX2 Therapeutics
Travel, Accommodations, Expenses – Alexion Pharmaceuticals